Research Output per year
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2002 2019
89Zr-immuno-PET: Towards a clinical tool to guide antibody-based therapy in cancer
Jauw, YWS., 19 Sep 2019Research output: Thesis › Research VU University Amsterdam, graduation VU University Amsterdam › Academic
89 Zr-immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo
Jauw, Y., o'Donoghue, J., Zijlstra, J., Hoekstra, O., Menke-van der Houven van Oordt, C. W., Morschhauser, F., Carrasquillo, J., Zweegman, S., Pandit-Taskar, N., Lammertsma, A., van Dongen, G., Boellaard, R., Weber, W. & Huisman, M., 30 May 2019, In : Journal of Nuclear Medicine. p. jnumed.118.224568Research output: Contribution to journal › Article › Academic › peer-review
Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis
Jauw, Y. W. S., Bensch, F., Brouwers, A. H., Hoekstra, O. S., Zijlstra, J. M., Pieplenbosch, S., Schröder, C. P., Zweegman, S., van Dongen, G. A. M. S., Menke-van der Houven van Oordt, C. W., de Vries, E. G. E., de Vet, H. C. W., Boellaard, R. & Huisman, M. C., 1 Aug 2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 46, 9, p. 1840-1849Research output: Contribution to journal › Article › Academic › peer-review
Open Access
Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
Rigter, L. S., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Zijlstra, J. M., van Imhoff, G. W., Poortmans, P. M. P., Beijert, M., Lugtenburg, P. J., Visser, O., Snaebjornsson, P., van Eggermond, A. M., Aleman, B. M. P., van Leeuwen, F. E. & van Leerdam, M. E., 2019, In : Cancer Medicine. 8, 1, p. 190-199 10 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access
Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study
Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 2019, In : Haematologica. 104, 4, p. e151-e153Research output: Contribution to journal › Comment/Letter to the editor › Academic
Open Access